When Merck and Schering-Plough released data from a clinical trial of cholesterol medication Vytorin showing that it worked no better than a much cheaper generic, the companies were widely accused in the media of deliberately delaying the release of the findings for 20 months in order to boost profits — prompting the U.S. Senate Finance Committee to investigate. The result: the SFC has widened its inquiry into pharmaceutical industry funding, including CME grants, to see if these monies are ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Senate Finance Committee Investigates Medical Societies’ Financial Ties to Pharma, you'll get exclusive access to a large archive of premium content.

Already registered? here.